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THE POPULATION COUNCIL
CENTER FOR BIOMEDICAL RESEARCH
A NONPROFIT PRODUCT-DEVELOPMENT ENTITY
CENTER FOR BIOMEDICAL RESEARCH (CBR)
For more than 60 years, research
conducted at the CBR laboratories has
addressed critical questions in sexual and
reproductive health and supported the
development of innovative products that help protect the health and
well-being of millions of people worldwide.
The Center’s researchers pioneered the field of long-acting reversible
contraception (LARCs), developing intrauterine devices (IUDs) such as
ParaGard® (the copper-T IUD) and Mirena®; implants such as
Norplant® and Jadelle®, and most recently, a contraceptive vaginal
system known as Annovera®; which have led to a series of
technological descendants. Today, more than 170 million women
worldwide are using contraceptive technologies developed at CBR or
based on CBR’s technologies.

OUR WORK

Located on the campus of
New York City’s Rockefeller
University, CBR is a vibrant hub of
scientific investigation and product
development.

The Center’s scientists are investigating new approaches to prevent
HIV and other sexually transmitted infections (STIs) and developing next-generation contraceptives and novel
multipurpose prevention technologies, or MPTs, which are products designed to prevent HIV, other STIs and,
in some cases, unintended pregnancy. Researchers are developing on demand and sustained release
formulations that deliver active pharmaceutical ingredients from fast-dissolving inserts, gels, intravaginal rings
(IVRs) and other innovative delivery systems that are designed to be safe, low-cost and easy to use.

OUR CAPABILITIES
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The Council’s experience in reproductive health, HIV and other STIs, basic science research, behavioral science,
and public health guides the Center’s efforts to develop the products that women and men need and will use.
The biomedical innovations developed at the Center’s labs have the potential to expand the options to improve
sexual and reproductive health significantly. CBR expertise includes product formulation, in which promising
drugs or combinations of drugs are loaded into novel drug delivery systems, and preclinical and clinical testing
of products to establish safety and efficacy. The Council has deep experience in regulatory and health systems
management, and in product introduction and social marketing, which helps ensure that the products
developed in our labs will be available to the people who need them most. The Council has seven FDA-approved
products, numerous patents and hundreds of publications in top peer-reviewed scientific journals. CBR
scientists are developing a rich pipeline of products, ensuring that men and women worldwide will have safe
and effective products that meet their sexual and reproductive health needs throughout the different stages
of their lives.

The Population Council conducts research and delivers solutions that improve
lives around the world. Big ideas supported by evidence. It’s our model for
global change. popcouncil.org
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OUR PARTNERSHIP
MODEL
CBR partners with
universities, government
institutions, other nonprofit research
organizations, service
delivery organizations,
contract research
organizations and
pharmaceutical companies
to develop, manufacture
and conduct clinical trial
testing.
Our model includes
research, co-development,
manufacturing, clinical trial
and material transfer
agreements. CBR does not
market any of our products
relying on partnerships
with pharmaceutical
companies to market and
distribute our products
which include provisions
for public sector pricing.
Our focus is on developing
long term partnerships
where mutual
commitments to products
can be realized.

SELECTED PRODUCTS IN DEVELOPMENT
Population Council researchers are pioneering bold approaches to reduce
sexually transmitted infections and unintended pregnancy by developing a
new generation of MPTs.
MPTs—fast-dissolving inserts, gels, and intravaginal rings—are designed to prevent
HIV, other STIs, and/or unintended pregnancy simultaneously, allowing women and
men to lead healthy sexual and reproductive lives.

Vaginal ring for the prevention of pregnancy and HIV
• Etonogestrel (ETG), ethinyl estradiol (EE), and QGriffithsin
(QGRFT) vaginal ring (EEQ IVR) is in preclinical phase
• GRFT is a naturally occurring algae-derived protein that inhibits
HIV and other pathogens, including HSV, and is the most potent
anti-HIV agent described in the literature
• GRFT could eliminate risk of HIV drug cross-resistance, as no other
antiretroviral with similar mode of action is used in treatment
• Collaboration with Oak Crest Institute of Science

Fast dissolving insert for the prevention of pregnancy and HIV
•
•
•
•
•

QGriffithsin, citric acid, lactic acid, sodium bitartrate
On demand contraception, hormone free
Does not impact bleeding profile
Provides protection for women with infrequent sex
Collaboration with PATH

Dual prevention pill for the prevention of pregnancy and HIV
• Provides protection for women against pregnancy and HIV by coformulating emtricitabine and tenofivir disoproxil fumarate (PrEP)
with levonorgestrel and ethinyl estradiol for contraception
• Designed to increase uptake of and adherence to PrEP especially
among high risk adolescent girls

CBR is developing new contraceptive methods to address the needs of the
142 million women with an unmet need for contraception and millions more
who are dissatisfied with their current method.
These contraceptives address the need for on demand contraception for infrequent
sex, male contraception, and potential better safety profiles, especially for heavier
and obese women.

Microneedle patch for on demand contraception
• Nestorone microneedle for on-demand contraception
• 4–6-day window of protection when used prior to coitus
• Target is minimal breakthrough bleeding if used less than once a
month

Nestorone/estradiol contraceptive 3-month ring
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• Estradiol could be a safer estrogen with potentially fewer side
effects, especially for heavier women
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